Evidence map›Paper›PMID 10525050›Full record

ArticleThe Journal of clinical investigation1999

Mutations in Igalpha (CD79a) result in a complete block in B-cell development.

Y Minegishi, E Coustan-Smith, L Rapalus, F Ersoy, D Campana, M E Conley

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of clinical investigation, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed, 1 pooled it
5.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 1 synthesis or guideline pooled it, 223 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Y MinegishiDepartments of Immunology, Hematology/Oncology, and Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA. yoshiyuki.minegishi@stjude.org
E Coustan-Smith
L Rapalus
F Ersoy
D Campana
M E Conley
St. Jude Children's Research Hospital · USUniversity of Tennessee Health Science Center · USHacettepe University · TR

Funding

Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9M
GENETIC ASPECTS OF IMMUNODEFICIENCIESR37AI025129 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CONLEY, MARY ELLEN · 1999 to 2007
$2.7M
NIH Genetic Aspects of ImmunodeficiencyR56AI025129 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CONLEY, MARY ELLEN · 2010 to 2010
$507k
GENETIC ASPECTS OF IMMUNODEFICIENCYR01AI025129 · NIAID · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI CONLEY, MARY ELLEN · 1987 to 1998
–
NCI NIH HHS P30 CA021765NCI NIH HHS P30 CA21765NIAID NIH HHS AI-25129NIAID NIH HHS R37 AI025129NIAID NIH HHS R56 AI025129
6 · The paper itself

Abstract

Mutations in Btk, mu heavy chain, or the surrogate light chain account for 85-90% of patients with early onset hypogammaglobulinemia and absent B cells. The nature of the defect in the remaining patients is unknown. We screened 25 such patients for mutations in genes encoding components of the pre-B-cell receptor (pre-BCR) complex. A 2-year-old girl was found to have a homozygous splice defect in Igalpha, a transmembrane protein that forms part of the Igalpha/Igbeta signal-transduction module of the pre-BCR. Studies in mice suggest that the Igbeta component of the pre-BCR influences V-DJ rearrangement before cell-surface expression of mu heavy chain. To determine whether Igalpha plays a similar role, we compared B-cell development in an Igalpha-deficient patient with that seen in a mu heavy chain-deficient patient. By immunofluorescence, both patients had a complete block in B-cell development at the pro-B to pre-B transition; both patients also had an equivalent number and diversity of rearranged V-DJ sequences. These results indicate that mutations in Igalpha can be a cause of agammaglobulinemia. Furthermore, they suggest that Igalpha does not play a critical role in B-cell development until it is expressed, along with mu heavy chain, as part of the pre-BCR.

Indexed as

MutationAgammaglobulinemiaAnimalsAntigens, CDB-LymphocytesCD79 AntigensChild, PreschoolFemaleHematopoietic Stem CellsHumansImmunoglobulin mu-ChainsMicePhenotypeReceptors, Antigen, B-CellReverse Transcriptase Polymerase Chain ReactionAntigens, CDCD79 AntigensCD79A protein, humanCd79a protein, mouseImmunoglobulin mu-ChainsReceptors, Antigen, B-Cell

Identifiers

PMID10525050
PMCPMC408581
OpenAlexW1966742362

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.